Clinical trials: Acute Phase
Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery
This clinical trial is designed to evaluate KELI-101 versus placebo for the prevention of acute kidney disease leading to chronic kidney disease in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- MesAKI (NCT06678399)
- Testing
- KELI-101
- Volunteers
- 91 people
- Sponsor
- Kelifarma
Late Effects, Testicular Germ Cell Tumor Mixed
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments.
- Conditions
- Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC
- Trial name
- PASCA (NCT04671693)
- Testing
- PASCA intervention
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Leon Berard
Acute Myeloid Leukaemia (AML)
Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
- Trial name
- NCT07867626
- Testing
- Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rutgers, The State University of New Jersey
AML, Adult
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
This is a first-in-human, dose-escalation and dose-expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of STI-8591 in subjects with advanced AML who have signed an informed consent…
- Trial name
- NCT05947344
- Testing
- STI-8591
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Infective Endocarditis, Response, Acute Phase
Personalized Medicine in Patients With Infective Endocarditis
The hypothesis underlying this work is the identification of different sub phenotypes of patients with infective endocarditis through the study of the host's response to infection.
- Conditions
- Infective Endocarditis, Response, Acute Phase, Treatment
- Trial name
- NCT04838938
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Fundación para la Investigación Biosanitaria del Principado de Asturias
COVID19 ARDS
Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome
Mesenchymal stem cells (MSCs) are of potential help in acute respiratory distress syndrome (ARDS), due to their anti-inflammatory properties.
- Trial name
- MSC-COVID19 (NCT04625738)
- Testing
- Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Central Hospital, Nancy, France
Leukemia, Acute Lymphoblastic Leukemia
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
This study is an investigational approach that uses immune cells, called "T cells", to kill leukemia. These T cells are removed from blood, modified in a laboratory, and then put back in the body.
- Trial name
- NCT01044069
- Testing
- gene-modified T cells targeted
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Migraine Disorders
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
- Trial name
- NP101-011 (NCT00723983)
- Testing
- Sumatriptan succinate, NP101 Study Patch
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NuPathe Inc.
Acute Ischemic Stroke, Cerebral Infarction
Safely Quenching Complement in Stroke Survivors
This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain.
- Trial name
- SUCCESS (NCT07495722)
- Testing
- Pegcetacoplan Injection [Empaveli]
- Volunteers
- 20 people
- Sponsor
- Columbia University
Polycythemia Vera, Essential Thrombocythemia
A Study of GLB-001 in Patients With Myeloid Malignancies
Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
- Trial name
- NCT06378437
- Testing
- GLB-001
- Where
- 14 sites in China
- Volunteers
- 108 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Respiratory Distress Syndrome, Adult
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome
This is a Phase 2b, randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in…
- Trial name
- STAT (NCT03818854)
- Testing
- Human Mesenchymal Stromal Cells, Cell Reconstitution Media
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Michael A. Matthay
Cerebral Stroke, Stroke, Acute
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
- Conditions
- Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
- Trial name
- NCT00061022
- Testing
- NXY-059
- Where
- 256 sites in United States, Argentina and 28 more
- Volunteers
- 3,200 people
- Sponsor
- AstraZeneca
Acute Low Back Pain
Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain
The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with acute low back pain.
- Trial name
- NCT04082975
- Testing
- NVP-1203, NVP-1203-R
- Where
- South Korea
- Volunteers
- 421 people
- Sponsor
- NVP Healthcare
Effect of Food, Malnourished Children
Local Dishes Versus Ready-to-use Therapeutic Foods Management of Severe Acute Malnutrition
In a context of frequent shortages of ready-to-use therapeutic foods (RUTFs), this study aimed at assessing the effectiveness of the use of local dishes in conjunction with nutritional education for children with severe acute…
- Trial name
- NCT06759883
- Testing
- local dishes using the my plate concept
- Where
- Cameroon
- Volunteers
- 30 people
- Sponsor
- University of Garoua
Low Back Pain
Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain
The purpose of this study is to evaluate efficacy, tolerability and safety of Etoreat®(Etodolac-Lidocaine Topical Patch) in the treatment of acute low back pain (LBP).
- Trial name
- NCT01968005
- Testing
- Etoreat®(Etodolac-Lidocaine Topical Patch)
- Where
- 7 sites in United States
- Volunteers
- 232 people
- Sponsor
- MEDRx USA, Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase…
- Conditions
- Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT04260022
- Testing
- Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab
- Where
- 9 sites in United States, Canada
- Volunteers
- 242 people
- Sponsor
- Ascentage Pharma Group Inc.
Spontaneous Intracerebral Hemorrhage
Stromal Vascular Fraction (SVF) Therapy in Patients With Acute Spontaneous Intracerebral Hemorrhage (SICH).
The purpose of this pilot study is to evaluate the safety of stromal vascular fraction (SVF) therapy in patients with spontaneous intracerebral hemorrhage (SICH).
- Trial name
- NCT05232903
- Testing
- SVF therapy group
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Tiantan Hospital
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.
- Trial name
- NCT01863186
- Testing
- Lofexidine HCl, Open Label Lofexidine HCL
- Where
- 18 sites in United States
- Volunteers
- 603 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06703073
- Testing
- Cohort A: vilobelimab, Cohort B: paridiprubart, Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- PPD Development, LP
Acute Myeloid Leukemia
A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia
The study will determine the maximal tolerated dose (MTD) of panobinostat administered in combination with a fixed combination of cytarabine (ara-C) and mitoxantrone in adult patients with relapsed or refractory acute myeloid…
- Trial name
- NCT01055483
- Testing
- panobinostat/LBH589B
- Where
- 6 sites in France, Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.